3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
128
Leukemia, Lymphocytic, Chronic, B-Cell
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Lymphoma, Non-Hodgkin
83
Lymphoma, Follicular
76
Lymphoma, Large B-Cell, Diffuse
71
Leukemia
60
Lymphoma, Mantle-Cell
51
Burkitt Lymphoma
48
Hodgkin Disease
44
Leukemia, Myeloid, Acute
42
Lymphoma, B-Cell, Marginal Zone
41
Lymphoma, B-Cell
40
Recurrence
38
Lymphoma, T-Cell, Cutaneous
27
Mycosis Fungoides
26
Myelodysplastic Syndromes
25
Waldenstrom Macroglobulinemia
24
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
24
Multiple Myeloma
21
Lymphoma, Large-Cell, Immunoblastic
21
Lymphoma, Large-Cell, Anaplastic
21
Sezary Syndrome
19
Neoplasms
19
Hematologic Neoplasms
18
Myeloproliferative Disorders
17
Lymphoma, Extranodal NK-T-Cell
16
Leukemia, Myelomonocytic, Chronic
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Leukemia, Biphenotypic, Acute
14
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Purpura, Thrombotic Thrombocytopenic
×
Lymphoid
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn